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Abstract
The role of laparoscopic radical cholecystectomy (LRC) in the surgical management of T2 gallbladder carcinoma (GBC) is still
controversial.
The medical records of patients with T2 GBC treated with radical cholecystectomy were retrospectively reviewed. In this study, we
compare the short- and long-term oncologic outcomes, using propensity score matching analysis, of patients with T2 GBC who
underwent LRC and open radical cholecystectomy (ORC).
Among 183 patients, 86 were selected by propensity score matching (LRC=43 and ORC=43). The ORC group underwent more
extensive surgery (liver resections and extended lymph node dissections [ELND]) than the LRC group. The LRC group had less
operative blood loss, shorter length of hospital stay, fewer complications, and had the earlier start of adjuvant chemotherapy. There
was no significant difference between the laparoscopic and open surgery groups in terms of 5-year overall survival rate (64.6% vs
80.4%, P= .214) and disease-free survival rate (77.1% vs 82.2%, P= .641). A subgroup analyses showed that liver resection and
ELND had no survival advantage compared to no liver resection and regional lymph node dissection, respectively.
Our LRC approach is safe and effective, with long-term survival comparable to that of ORC.
Abbreviations: AJCC = American joint committee on cancer, ASA = American Society of Anesthesiologists, BMI = body mass
index, CA = cancer antigen, CEA = carcinoembryonic antigen, CT = computed tomography, DFS = disease-free survival, ELND =
extended lymph node dissection, EUS = endoscopic ultrasound, GBC = gallbladder cancer, LRC = laparoscopic radical
cholecystectomy, MRI=magnetic resonance imaging, ORC= open radical cholecystectomy, OS= overall survival, RLND= regional
lymph node dissection.
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1. Introduction
Complete surgical resection remains the optimal treatment for
gallbladder cancer (GBC). Simple cholecystectomy, either
through an open or laparoscopic approach, for early T1a tumors
is an adequate treatment as long as proper tissue handling is
observed in order to avoid tumor spillage.[1,2] For a patient with a
T1b or more advanced tumor, open radical cholecystectomy
(ORC) remains the recommended curative treatment.[3,4]
The role of laparoscopic radical cholecystectomy (LRC) in the
surgical management of gallbladder cancer remains controver-
sial. In the era of minimally invasive surgery, the laparoscopic
surgical approach is now widely adopted in different gastroin-
testinal malignancies.[5–7] However, most surgeons remain
skeptical about adopting the laparoscopic approach in the
surgical management of GBC. Some of the possible reasons
include the risk of tumor spillage and dissemination,[8,9] port-site
recurrences,[10] and complexity of lymphadenectomy and liver
resection.
Several studies have suggested the oncologic feasibility of the
laparoscopic approach in the treatment of T2 GBC.[11] As long as
the oncologic principles of open surgery are followed, LRC can
be potentially applied to achieve a comparable oncologic
outcome to that of the open approach for T2 GBC.
In this study, patients with T2 GBC who underwent LRC and
patients with T2 GBCwho underwent ORCwere compared after
a propensity score matching (PSM) analyses. The primary aim
was to compare the long-term outcomes (overall survival [OS]
and disease-free survival [DFS]) of patients with GBC and ORC.
The secondary aim was to compare the short-term outcomes
(intraoperative and post-operative).
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2. Materials and methods
2.1. Study design
The medical records of patients with GBC who underwent
surgical procedures at the Yonsei University Health System in
Seoul, Korea, between 2005 and 2017 were retrospectively
reviewed using the electronic medical records database. We
identified 183 patients with pathologically confirmed T2 GBC
who underwent radical cholecystectomy. Exclusion criteria were
incomplete clinical and histologic data, patients who underwent
combined common bile resection, and grossly involved aorto-
caval lymph nodes on preoperative Computed Tomography scan.
The study protocol was approved by the Yonsei Institutional
Review Board and the need for written informed consent was
waived.
2.2. Data collection
Demographic data such as age, sex, and clinical presentation
including the presence of symptoms were recorded. The
preoperative serum cancer antigen 19-9 (CA 19-9) and
carcinoembryonic antigen (CEA) levels and pathologic data,
such as tumor location, size, grade, lymph node status, and
lymphovascular and perineural invasions, were reviewed. The
8th edition of the American Joint Committee on Cancer Staging
Manual (AJCC) was used for cancer staging.[12] In this cohort,
regional lymph node dissection (RLND) includes dissection along
the cystic duct, pericholedochal, posterosuperior pancreatico-
duodenal, retroportal, and hepatic artery node groups, whereas
extended lymph node dissection (ELND) includes RLND plus
aortocaval (16A and B) lymph node dissection.
2.3. Indication and for LRC
The indication for surgery and the type of approach were
discussed for every patient during weekly hepatobiliary and
pancreas conference. Patients with suspected GBC in preopera-
tive imaging, either with transabdominal ultrasonography or
computed tomography scan, underwent further imaging evalua-
tions such as endoscopic ultrasonography, magnetic resonance
imaging, and positron emission tomography scan for proper
clinical staging prior to surgery. Likewise, patients with an
incidental finding of GBC after a laparoscopic cholecystectomy
subsequently underwent further imaging evaluations such as
magnetic resonance imaging and positron emission tomography
scan before the re-operation.
2.4. Surgical technique
LRC was performed through 5 abdominal ports, with the patient
in a reverse Trendelenburg position and tilted to the lateral left. A
12-mm trocar was placed at the umbilicus, and pneumo-
peritoneumwas established. Staging laparoscopy was performed;
if there was no sign of distant metastasis, the additional 4 trocars
were inserted (Fig. 1). Full kocherization was performed, and
aortocaval fatty tissue was sampled and sent for frozen section
analysis. If the frozen section was negative for tumor, radical
resection was continued. Simple cholecystectomy was performed
if no evidence tumor invasion on the liver bed, otherwise wedge
liver resection with at least a 1-cm margin from the gallbladder
bed. However, whether to perform wedge liver resection and
aortocaval lymph node dissection or not was at the discretion of
the surgeon and was not routinely performed in our institution.
Cystic duct margin was sent for frozen section, and if positive for
tumor, common bile duct resection was indicated. Lymphadenec-
tomy was performed to include all lymph nodes from the
common hepatic artery up to the right and left hepatic arteries,
skeletonizing the structures in the hepatoduodenal ligament and
all nodes in the retropancreatic area. Specimens were collected
using an endo-pouch.
For ORC, a J-shaped right subcostal incision was performed.
Also, liver resection (wedge resection or segment 4b/5) was not
routinely performed for gallbladder cancer with no liver bed
invasion by frozen section. Likewise, the extent of lymphadenec-
tomy depended on the preference and intraoperative decision of
the surgeons. Some surgeons performed the ELND in patients
without intraoperative evidence (by frozen section) of metastasis,
and liver resection in patients without evidence of liver invasion
(T2 GBC in frozen section).
2.5. Primary endpoints
The primary endpoints of this study were the long-term survival
and short-term outcomes of patients with T2 GBC treated with
LRC or ORC. OS was calculated from the date of surgery to the
date of death or last follow-up. Patients were also followed up
regularly for serum CA 19-9 and CEA level determination and
computed tomography scan, to detect tumor recurrence. DFSwas
calculated from the date of surgery to the date of recurrence or
last follow-up. Short-term outcomes were determined on the
basis of postoperative complications and classified according to
the Clavien-Dindo classification, lengths of hospital stay, and
early start of adjuvant chemotherapy.
2.6. Literature review
A detailed searched in PubMed, Web of Science and Cochrane
Library for studies of LRC for T2 gallbladder cancer to compare
to our result in terms of 5-years survival rate. Search terms were
titled to Title or Abstract: “gallbladder cancer” or “T2
gallbladder cancer” and “laparoscopic” OR “laparoscopy”.
Figure 1. Placement of trocars in laparoscopic radical cholecystectomy.
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2.7. Statistical analysis
To decrease the risk of confounding bias in this cohort, patients in
the LRC and ORC group were matched using PMS using the
NCSS 12 Statistical Software (NCSS, LLC. Kaysville, UT).
Propensity scores were estimated by logistic regression analysis,
with treatment strategy group (LRC vs ORC) as dependent
variable andage, sex,ASAscore, BMI score, preoperativeCEAand
CA 19-9 level, and tumor location as independent variables.
Matching was performed according to the “nearest neighbour”
method using a 0.2-width caliper, and at a1:1 ratio.
Further statistical analysis was performed using IBM SPSS
Statistics, version 22 (SPSS Inc., Chicago, IL). Categorical
variables were expressed as frequencies (%), whereas continuous
variables were presented as means with their range or ±standard
deviation. The means of continuous variables were compared
using an independent sample t test. Categorical variables were
compared using the Pearson x2 test. OS was calculated on the
basis of the time from surgery to death or last follow-up. OS and
DFS were estimated using the Kaplan–Meier method and
compared using a log-rank test.
3. Results
3.1. Patients’ characteristics
A total of 183 patients with T2 GBC underwent radical
cholecystectomy from 2005 to 2017, comprising 128 (69.9%)
ORC and 55 (30.1%) LRC. Figure 2 shows the number of cases
of LRC performed from 2005 to 2017. The choice of LRC over
ORC has been steadily increasing according to time period.
Figure 3 summarizes the process of PMS. Among 183 patients,
142 were included in the analysis. Baseline characteristics of the
pre-matched and post-matched groups are detailed in Table 1.
Although not statistically significant, patient on the ORC group
had more elevated CEA and CA 19-9 level compared to LRC
group. After PMS, 86 matched patients were observed (n=43 for
both LRC and ORC group). There were no significant group
differences in the baseline clinicopathologic characteristics such as
age, ASA score, BMI, tumor location, tumor size, grade, and
lymphovascular and perineural invasion were similar between the
groups. In particular, the CEA and CA 19-9 showed a very similar
level between the two groups after matching (P= .345 to P= .707,
respectively). Likewise, both groups had received similar adjuvant
chemotherapy. Notably, the surgical approach (liver resection and
extent of lymph node dissection) was significantly different
between the two groups. Although majority of the patients (n=
61, 70.9%) underwent simple cholecystectomy, patients in the
LRC group mostly received simple cholecystectomy only com-
pared to the ORC group (84% vs 53%, respectively). Moreover,
patients in the ORC group mostly underwent ELND compared to
LRC group (65.1% vs 19.4%, respectively).
3.2. Primary endpoint: long-term oncologic outcomes
3.2.1. LRC vsORC.At amedian follow-up of 32months (2–125
months), there was no difference between the LRC and ORC
groups in terms of 5-year OS and 5-year DFS. The 1-, 3-, and 5-
year OS was 97.6%, 72.6%, and 64.0% for the LRC group and
97.3%, 87.0%, and 80.4% for the ORC group, respectively
(P= .214) (Fig. 4A). Similarly, the 1-, 3-, and 5-year DFS rate after
a curative-intent resection was 92.3%, 82.6%, and 77.1% for
LRC and 89.7%, 87.0%, and 82.2% for the ORC group,
respectively (P= .641) (Fig. 4B). There was no reported trocar site
tumor recurrence or tumor dissemination among the LRC group.
3.2.2. Liver resection vs no liver resection. Since most patients
in this cohort underwent simple cholecystectomy only, particu-
larly those patients in the LRC, we investigated the oncologic
long-term benefit of liver resection in patients with T2 GBC.
Figure 5 illustrates the long-term oncologic outcomes between
patients who underwent liver resection and no liver resection.
There was no 5-year OS advantage in liver resection and no liver
resection (51.8 vs 57.2 months, P= .154).Similarly, there was no
5-year DFS advantage between patients who underwent liver
resection and no liver resection (51.3 vs 52.2 months, P= .730).
Among patients who underwent no liver resection, there was no
evidence of residual tumor on the liver bed and on final pathology
report. In addition, no evidence of tumor recurrence on the
gallbladder bed on patients who had no liver resection. In fact,
the 2 liver recurrences in this cohort were observed on 2 patients
who had wedge resection and segment 4b/5 resection in segment
8 and 3, respectively. The presence of micro metastasis was also
not observed on the final pathology of the resected liver.
Moreover, among 58 (67.4%) patients with tumor located in
the liver side, 16 (27.8%) underwent liver resection while 42
Figure 2. Proportion of patients with T2 gallbladder cancer who underwent laparoscopic radical cholecystectomy and open cholecystectomy from 2005 to 2007.
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(72.4%) patients did not undergo liver resection. However, liver
resection was not associated with improved 5-year DFS (50.4 vs
48.2 months, P= .865) and 5-year OS (51.8 vs 55.4 months,
P= .254) (Fig. 5C and D), respectively.
3.2.3. RLND vs ELND. We also evaluated the long-term survival
advantage of ELND compared to RLND. Among 86 patients, 31
(40.7%) underwent ELND in this cohort. Themean 5-year DFS of
patients with RLND is comparable to those patients with ELND
(50.8 vs 53.0months,P= .665) (Fig. 6A). Likewise, therewasno5-
year OS advantage between ELND and RLND (52.1 vs 54.6
months, P= .951) (Fig. 6B). The incidence of tumor recurrence in
the aortocaval area (station 16A and B lymph nodes) was also not
statistically different in patientswith onlyRLND(2/6, 25%)and in
those with ELND (3/3, 50%) (P= .334). As such, ELND has no
survival advantaged compared to RLND alone.
3.3. Secondary endpoints: short-term outcomes
3.3.1. Pathologic outcome.According to the AJCC 8th edition,
there were no significant differences between the laparoscopic
and open surgery groups according to pN0, pN1, and pN2 status
in the final pathology report (P= .518). Although significantly
more lymph nodes were harvested during ORC than during LRC
group (6.12±5.78 vs 11.93±7.03, P= .0001), the metastatic
lymph node to retrieved lymph node ratio was not statistically
significantly different between the LRC group and ORC group
(15.7% vs 8.13%, P= .208). Notably, among 35 (40.7%)
patients (7 in the LRC, and 28 in the ORC) who underwent
ELND, none of them had tumor metastasis on the aortocaval
lymph nodes (station 16A and 16B). Moreover, the presence of
microscopic residual disease (R1 resection) was not significantly
different between the 2 groups (ORC, 3 vs LRC, 2, P=1.000). All
the microscopic residual disease was noted at the resection
margin of the cystic duct on the final pathology.
3.3.2. Perioperative outcome. The mean operative time was
significantly shorter, blood loss was less, the length of hospital stay
was shorter, and adjuvant therapy was started earlier in the LRC
group than in the ORC group (P=<.05). There were also more
complications, on the basis of the Clavien-Dindo classification, in
the ORC group, including chyle leak and intra-abdominal
infections, than in the laparoscopic surgery group (P= .050)
(Table 2). There was no reported 30 days mortality.
3.4. Literature review about LRC in T2 GBC
Table 3 summarizes the long-term outcome of patients with GBC
treated with LRC from single-institution experienced. Although
different methods were used to achieve a negative liver bed
Figure 3. Flowchart of patients with T2 gallbladder cancer included in the study and propensity score matching process.
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margin, the reported 5-year OS rates for T2 gallbladder cancer
ranged from 50% to 90%.[13–18] Our laparoscopic approach
(either simple cholecystectomy or liver resection and regional
lymphadenectomy), however, had comparable long-term out-
comes with other studies.
4. Discussion
The standard of care for the treatment of T2 GBC is still ORC,
which includes en bloc liver resection (wedge or segment 4b and
5), and regional lymphadenectomy. However, with increasing
expertise and advances in instrumentation in minimally invasive
surgery, surgeons have now been exploring the efficacy and safety
of the laparoscopic approach in the treatment of GBC.[19–21]
Nevertheless, because of the innate complexity of the procedure
and the concern for potential tumor dissemination during the
procedure,[22] LRC was only performed in high volume centers
with expert hepatobiliary surgeons.[23]
In our center, we employ laparoscopic approach in suspected
T1 and T2 GBC. A proper preoperative imaging, including CT
scan, magnetic resonance imaging (MRI), and endoscopic
ultrasound (EUS) to assess the extent of the tumor invasion is
of paramount importance in the decision making whether or not
to do extended cholecystectomy. Notably, 61 (71%) patients in
Table 1
Clinicopathologic characteristics between the laparoscopic surgery and open surgery groups before propensity score matching.
Pre-matched Post-matched
Clinicopathologic characteristics LRC (n=54) ORC (n=88) P LRC (n=43) ORC (n=43) P
66.5±10.5 64.7±8.08 .253 66.7±10.3 65.4±7.6 .669
Gender
Male 30 51 .799 25 28 .506
Female 24 37 18 15
Incidental
No 44 63 .184 37 32 .279
Yes 10 25 6 11
ASA score
1 15 25 .292 14 16 .804
2 32 46 25 22
3 5 17 4 5
BMI, kg/m2 (mean)
<18 3 4 .063 2 3 .898
18–25 40 54 34 33
25–30 11 24 7 7
>30 0 6 0 0
CA 19-9, U/mL (mean) 19.6±22.8 27.2±51.9 .345 20.3±23.5 22.9±37.7 .707
CEA, ng/mL (mean) 2.2±1.2 3.4±11.9 .211 2.2±1.2 1.9±1.0 .212
Tumor location
Hepatic side 33 63 .195 27 31 .357
Peritoneal side 21 25 16 12
Tumor size, cm (mean) 4.5±3.1 4.5±2.9 .940 4.8±3.1 4.9±2.9 .801
PNI
No 35 56 .443 28 25 1.000
Yes 6 6 3 2
LVI
No 31 55 .303 27 22 .286
Yes 11 12 5 8
Grade
Well/moderately differentiated 48 74 .652 38 34 .675
Poorly/undifferentiated 5 10 4 6
Residual disease
No 50 85 .293 40 41 1.000
Yes 4 3 3 2
Adjuvant chemotherapy
No 35 66 .157 27 30 .494
Yes 19 21 16 13
Surgical approach
Liver resection
No 47 41 .0001 38 23 .001
Wedge 7 32 5 12
4b/5 0 15 0 8
Extent of LND
Regional 44 26 .0001 36 15 .0001
Aortocaval 10 62 7 28
AJCC=American Joint Committee on Cancer, ASA=American Society of Anesthesiologists, BMI=body mass index, CA= cancer antigen, CEA= carcinoembryonic antigen, LND= lymph node dissection,
LRC= laparoscopic radical cholecystectomy, ORC= open radical cholecystectomy.
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Figure 5. Comparison between liver resection and no liver resection in T2 gallbladder carcinoma according to tumor location. (A) 5-year disease-free survival
between liver resection and no liver resection in patients with liver-side tumors. (B) 5-year overall survival between liver resection and no liver resection in patients
with liver-side tumor. (C) Disease-free survival between liver resection and no liver resection in patients with liver-side tumor. (D) 5-year overall survival between liver
resection and no liver resection in patients with liver-side tumor.
Figure 4. Kaplan–Meier survival curves of patients with T2 gallbladder carcinoma after curative-intent radical resection. (A) Comparison of 5-year disease-free
survival between laparoscopic and open radical cholecystectomy group. (B) Comparison of overall 5-year survival between laparoscopic and open radical
cholecystectomy group.
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this cohort underwent only cholecystectomy with lymph node
dissection, and only 25 of 47 patients (29%) underwent liver
wedge resection with at least a 1-cm margin. Previously, Kim
et al[24] reported that reported that simple cholecystectomy and
lymph node dissection without liver resection in patients with T2
GBC had the same OS as well as recurrence pattern compared to
extended cholecystectomy (wedge or segment 4b/5 resection).
There were several reports of various laparoscopic approaches in
establishing a negative margin on the liver bed with acceptable
oncologic outcomes. These included simple cholecystectomy
Table 2








Operative time, minutes (mean) 139.05±97.09 211.16±91.36 .001
Blood loss, mL (mean) 71.63±178.77 208.14±242.165 .004
Blood transfusion
No 43 40 .039
Yes 0 3
Post-operative outcome
Length of hospital stay, days (mean) 6.05±9.846 12.58±5.504 .0001
Days from operation to start the start of
adjuvant chemotherapy, days (mean)
25.28±71.14 38.58±15.57 .014
Complications (Clavien–Dindo classification)





Retrieved lymph nodes (mean) 6.12±5.78 11.93±7.03 .0001
Lymph node ratio (%) 15.7% 8.13% .208
AJCC 8th pN
0 32 29 .518
1 11 13
2 0 1
AJCC 8th TNM stage





No 40 41 1.000
Yes 3 2
AJCC=American Joint Committee on Cancer.
Figure 6. Kaplan–Meier survival curves of patients with T2 gallbladder carcinoma according to extent of lymph node dissection. (A) Comparison of 5-year disease-
free survival between regional and extended lymph node dissection. (B) Comparison of 5-year overall survival between regional extended lymph node dissection.
Navarro et al. Medicine (2020) 99:20 www.md-journal.com
7
only, whole-layer cholecystectomy,[25] 2-mm thickness liver
resection margin,[18] >1cm liver bed margin,[26] and segment
4b/5 resections.[27] Until recently, there remains no consensus
about the extent of liver resection (wedge resection vs segment 4b/
5 resection).[28]
Interestingly, our results showed that there was no significant
difference in the DFS andOS between patients with liver resection
and those with no liver resection. In addition, patients with a
liver-side tumor who underwent liver resection (wedge or
segment 4b/5) either through a laparoscopic approach or open
surgery had no survival advantage over patients who did not
undergo liver resection. This is contrary to the findings of other
recent studies demonstrating that liver-side tumors portend
worse survival compared with peritoneal-side tumors[29,30] and
may benefit from liver resection.[30] However, the present study
may suggests that a simple cholecystectomy with lymphadenec-
tomy can be oncologically safe and effective in well-selected
patients, as survival may not be affected by the tumor location.[31]
Although the optimal extent of lymphadenectomy for radical
cholecystectomy is still controversial,[28] several studies had
suggested that an adequate lymphadenectomy includes a RLND,
which includes the cystic duct, pericholedochal, posterosuperior
pancreaticoduodenal, retroportal, right celiac, and hepatic artery
node groups.[32–35] It was observed in our study that ELND was
commonly performed among those who underwent ORC. Thus,
more lymph nodes were harvested in the open group than in the
laparoscopic group. Nevertheless, the mean number of lymph
nodes harvested in the laparoscopic group was 6.12, which is
equal to the recommended number (at least 6 lymph nodes) for
adequate staging and prognostication.[36,37] In addition, our
results showed no survival benefit of ELND over RLND.
Our analysis was based on a retrospective review of data, with
unavoidable bias. First, patients in the ORC group underwent
extensive surgery (liver resection and ELND) compared to LRC
group. This selection bias undoubtedly affects the short-term
outcomes in this cohort. As such, patients who underwent LRC
had a shorter length of hospital stay and fewer postoperative
complications. Moreover, patients in the LRC group started with
adjuvant therapy earlier than patients who underwent ORC.
Nevertheless, our findings emphasized that this extensive surgery
is not necessary for T2 GBC for the following reasons: first, using
the more extensive approach provides no long-term survival
benefit; second, although more lymph nodes were harvested in
the ORC, our laparoscopic approach provided adequate lymph
nodes harvested for proper prognostication. In the recent British
Phase III BILCAP study, adjuvant capecitabine has been shown to
significantly improve survival on patients with biliary tract
cancer and should be offered after surgery.[38] Thus, an early
start of adjuvant chemotherapy would be the fundamental
advantage of our minimally invasive surgery approach over open
surgery. Second, the sample size was small and the selection of
patients who underwent either laparoscopic surgery or open
surgery was not randomized. Thus, to properly assess the
efficacy, safety, and oncologic significance of LRC, a further
randomized study should be conducted. However, when
considering the rarity of gallbladder cancer, to our knowledge,
this study included the largest number of patients with T2 GBC
who underwent LRC.
5. Conclusion
Our laparoscopic approach allows for a shorter length of hospital
stay, results in fewer postoperative complications, and an earlier
start of adjuvant chemotherapy. The 5-years OS and DFS of
patients with T2 GBC after LRC is comparable to those of
patients treated with ORC. In addition, extensive surgery has no
survival advantage over simple cholecystectomy plus RLND for
T2 GBC. Further studies are needed to validate these findings.
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Choi et al[17] Retrospective 32∗ ORC Not specify Regional T2 51.8
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